LUPIN : Making or Breaking?1. Key Analysis and Levels
Wave C Completion Zone (₹1946-1982):
The price has reached a potential corrective Wave C termination area, which often acts as a demand zone where buyers re-enter.
This zone is a high-probability reversal region based on Elliott Wave principles.
Stop Loss Level (₹1924):
Positioned below the Wave C correction zone to manage risk in case of further downside.
Protects against potential failure of the demand zone.
First Target Zone (₹2245-2277):
Represents the extended retracement of Wave B and serves as a logical resistance zone for profit booking.
Change of Character (CHoCH):
A CHoCH signal (change from lower lows to higher highs) could confirm the start of a new bullish wave.
2. Trade Setup
A. Long Trade Setup:
Why Long?
The price has reached a critical demand zone (₹1946-1982) with potential for reversal.
The CHoCH zone suggests a possible trend change to bullish.
Entry: Around ₹1980-2000, upon observing bullish price action (e.g., hammer candlestick, engulfing patterns).
Stop Loss: ₹1924, ensuring minimal risk if the correction extends.
Targets:
₹2245-2277: Key resistance zone at the extended retracement of Wave B.
Trailing stops can be used for further upside beyond ₹2277.
B. Short Trade Setup (If Demand Zone Fails):
Why Short?
A strong breakdown below ₹1924 could indicate the demand zone has failed, leading to continuation of the downtrend.
Entry: Below ₹1924 after confirmation of breakdown with volume.
Targets:
₹1850: Immediate support from prior structure.
₹1720-1750: Deeper demand zone.
Stop Loss: ₹1970 to avoid being caught in a false breakdown.
3. Explanation of Analysis
Wave C Completion:
The corrective Wave C often concludes near key Fibonacci retracement levels, aligning with ₹1946-1982 here.
This zone has historical relevance as a demand area.
CHoCH Confirmation:
A breakout and higher high beyond the consolidation range would validate bullish sentiment.
Risk-Reward Dynamics:
Well-defined stop loss and target zones ensure favorable risk-to-reward setups for both long and short trades.
4. Confirmation Signals
For Long Entry:
Price stability and bullish reversal signals (e.g., RSI divergence, bullish engulfing candles) in the ₹1946-1982 zone.
A confirmed breakout above ₹2020 would further validate the trend reversal.
For Short Entry:
A decisive close below ₹1924 with high volume and bearish momentum.
5. Risk Management
Limit risk to 1-2% of your trading capital per trade.
Use scaling techniques to lock partial profits at the first target zone, trailing stop losses for additional gains.
Why This Plan Works
This trading strategy combines Elliott Wave analysis, demand-supply dynamics, and structured price levels to anticipate a potential bullish reversal. It also incorporates a contingency plan for a bearish breakdown, ensuring preparedness for all market scenarios.
Lupinindia
Lupin Long-Term Investment IdeaAs we can see on the month chart stock breakout it rounding bottom after a many years with very good volume and retesting. Bullish crossover on November 2023
Technical Analysis & indicators 🔍
Monthly Chart
Rounding Bottom
Educational content 📖
This stock analysis is designed for educational purposes and should not be taken as financial advice. Please carry out your own research or consult with a financial advisor before investing.
Visit the website and check fundamental
LUPIN - Stock AnalysisLupin Ltd. is showing a strong technical and fundamental profile, making it an interesting prospect for investors.
From a technical perspective, the stock exhibits several "Strong Bullish" signals. The HighLow indicator suggests "Strong Bullish" sentiment, with the stock near a one-year high and likely to make a new high. The daily candlestick pattern reflects "Strong Bullish" sentiment, and the monthly candlestick pattern also displays "Strong Bullish" signals.
In terms of resistance, the stock has encountered medium-term resistance levels, with top points at 1200.0 on October 19, 2023, 1174.2 on October 3, 2023, and 1155.65 on September 14, 2023.
From a fundamental perspective, Lupin Ltd. has several positive attributes. The company's net profit has seen a significant turnaround, shifting from negative to positive, indicating an improved financial performance. The Piotroski F Score is at a stable value of 5.0, which suggests sound financial health.
Furthermore, the company's net profit has been consistently increasing for the last five quarters, and the same holds for Profit Before Tax, demonstrating strong operational performance. There has been steady growth in earnings per share (EPS) over the last four quarters.
Lupin Ltd. offers a very low dividend yield of 0.350%, indicating a preference for reinvesting profits for growth. Additionally, there is a short-term positive trend in total sales and net profit. The company has achieved annual sales growth for three consecutive years, and quarterly sales over the last five years are trending upward.
In summary, Lupin Ltd. presents a promising investment opportunity with strong technical and fundamental indicators. The stock's bullish technical signals, coupled with its improving financial performance and consistent growth, make it an attractive choice for investors seeking potential growth and value in the market. Nevertheless, investors should stay vigilant and monitor developments in both technical and fundamental aspects for a comprehensive understanding of the stock's potential.
Go Long above 1184.10
Stop Loss 1095
NSE:Lupin -trend change on card???
NSE:LUPIN
Lupin Limited is an India-based pharmaceutical company. The Company develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the United States, India, South Africa, and across the Asia Pacific, Latin America, and others. It offers vitamins, minerals, supplements and neurological products. It has presence in the cardiovascular, dialectology, asthma, paediatrics, central nervous system, gastro-intestinal, anti-infectives and nonsteroidal anti-inflammatory drug therapy segments. Its complex generics portfolio includes Filgrastim, Peg-Filgrastim, Etanercept and Albuterol, and others. Its biosimilar products include Filgrastim, Peg-Filgrastim and Etanercept. Its specialty products consist of Solosec and NaMuscla. Its over-the-counter products include Softovac, Lupizyme, Aptivate, Lupisafe, Be One, V-Bath, and others. It supplies APIs for anti-retroviral, anti-malarial and others.
Disc: Invested, please do you own research
LUPIN - Long viewWith prices closing above all the important EMA the stock is looking technically strong. One can look to enter the trade above 771 with a target of 848 keeping a stop loss of below 732. RSI is reaching almost at the 60 level mark. Once sustains above the mark the stock should give some momentum. Wait for RSI to move above 60 on the DTF.
The views presented are of the author and are for educational purpose only . Kindly consult your financial advisor before investing.
LUPIN - Weekly AnalysisStock holds a good support near 790-800 levels, the same levels acted as strong resistance in the past and when crossed stock did spend some time near those levels and then moved upside.
Hence any dip in the stock if happens , price action near those levels should be watched carefully.
Lupin on weekly chart looking weak.NSE:LUPIN
Lets Read The Chart And Observe It
If you see the tail candle of 9th March 2020 week you can clearly see prices was rejected from the low of 504 and close at 605 volume was also good (Above Average).
Next candle of 16th march 2020 is also bullish candle with higher volume than previous candle. The 23th march 2020 candle was strong bearish candle form in supply area of 9th March candle.
Now come to the candle of 30th march nice strong bullish candle every retailer or price action trader who don't respect volume will now start thinking bull run has started, and start buying at any price they are getting. But look at volume its a above average volume but lover than previous volume. In the same week of 30th March 2020 we all started to see or hear from every source that Pharma Stock are going to boom on bias of COVID19, India will be supplying medicines to U.S and other major countries. And retailers started getting in and start buying.
Prices were getting higher till the week of 13th April 2020. Volume is still higher (Slightly Lower Than Previous Candle Volume) enough but range of the candle is now get narrow than all previous candles we observe till now. There also a good wick to this candle which clearly start indicating someone is start capping the prices or supply getting over the demand. Clearly at this point stock is weak.
Now let we see what happens in next two candles.
Candle of 20th April 2020 week one can immediately say its a bullish candle as it's closes higher with the highest volume we have seen and also a tail which indicate strong bullish sentiments. But can anyone think why the range is gets narrowed than previous bullish candles. Again clear indication of supply is happening in background. And we are now also in a territory of consolidation happened previously.
Now lets see what happened in last week (27th April 2020). Candle with tail gap up open at 899.95 make high of 906 find strong resistance at 901.75 made low of 811.55 closes near the low 835.30 volume above average not abnormal clear indication Bear Taken Over The Bull Move.
Note: 817.3 Is Support Level So We Can See Some Consolidation Between 817-901 Before Downtrend Started In Lupin.
Lupin - Long Trade - Investment - Price ActionPrevious Lupin short term trade stop los hit.
However this chart is for Medium to Long Term perspective.
Good buy zone 973-993
De-risk the trade at 1050 and continue to hold for bigger targets of 1160, 1309 and 1400+
Price is now at second/strong support of 973-993 after breaking previous support of 1010-1020.
Pharma sector had its bad days since last 2years, but now they have cope up the situation and we are seeing a good hold back in prices, making it the best bet again for coming months/years.